2024 World Conference on Lung Cancer (WCLC) - Posters-P3.06E.03 Anlotinib Mediated Inflammation Response Through NFKB/TNFRSF11A Cascade in Lung Cancer

Pdf Summary

This study examines the role of Anlotinib in mediating the inflammatory response through the NFKB/TNFRSF11A cascade in lung cancer. Specifically, it focuses on advanced non-small cell lung cancer (NSCLC). Anlotinib is highlighted as a promising anti-tumor drug due to its effects on anti-angiogenesis and proliferation inhibition, achieved by selectively inhibiting various tyrosine kinase receptors such as VEGFR, PDGFR, and FGFR. Despite being a valuable treatment for NSCLC, the study underscores the necessity for further exploration of potential biomarkers to predict patient responsiveness to Anlotinib due to the complexity of angiogenesis signal transduction.<br /><br />To investigate these effects, the researchers established a patient-derived xenograft (PDX) model of NSCLC and administered Anlotinib. They conducted transcriptome analysis to observe changes in gene expression and activation levels in molecular pathways that contribute to Anlotinib’s anticancer effects. Additionally, in vitro cell experiments demonstrated that Anlotinib's anticancer benefits are connected to NFκB pathway activation and the expression of cytokines IL1B and TNFRSF11A. Furthermore, serum samples from patients were analyzed using ELISA to confirm the relevance of these cytokines in Anlotinib's anticancer efficacy.<br /><br />Key findings from the study include differential gene expression in the NFKB pathway linked to Anlotinib efficacy. The results suggest a positive correlation between reduced levels of TNFRSF11A/IL1B and the drug’s effectiveness. The study also indicates that high mRNA levels of IL1B and TNFRSF11A in the TCGA cohort of NSCLC patients are associated with poor clinical outcomes. These insights support the potential clinical application of IL1B and TNFRSF11A expression levels as predictors of response to Anlotinib.

Asset Subtitle

Yidan Chen

Meta Tag

Speaker Yidan Chen

Topic Pathology & Biomarkers

Keywords

Anlotinib

NFKB

TNFRSF11A

NSCLC

anti-angiogenesis

tyrosine kinase receptors

VEGFR

PDGFR

FGFR

biomarkers